세계 혈우병 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Hemophilia Treatment Market is presumed to reach the market size of nearly USD 29.82 Billion by 2032 from USD 17.32 Billion in 2023 with a CAGR of 6.22% under the study period 2024-2032.

Hemophilia is a rare genetic disorder that features the inability of blood to clot properly, leading to prolonged bleeding after injuries or surgeries. Hemophilia treatment involves therapies designed to replace or enhance deficient clotting factors in the blood. These treatments include clotting factor concentrates, which can be derived from blood plasma or produced through recombinant DNA technology. Additionally, gene therapy is promising in providing a long-term solution by correcting the underlying genetic defect. Effective management of hemophilia is crucial for preventing and controlling bleeding episodes, thereby improving patients' quality of life.

MARKET DYNAMICS

The increasing prevalence of hemophilia, with approximately 1 in 10,000 individuals affected globally, drives the demand for effective hemophilia treatment options. Advances in recombinant factor therapies and the development of novel gene therapies offer significant opportunities to improve patient outcomes and provide a cure. For instance, recent innovations in gene therapy have demonstrated promising results in clinical trials, offering the potential for long-term solutions. Additionally, increasing awareness and better diagnostic capabilities contribute to early detection and treatment, further driving hemophilia treatment market growth. Supportive government initiatives and funding for research also provide opportunities for the continued development and accessibility of advanced therapies. However, the high cost of innovative therapies and limited access in developing regions may restrain hemophilia treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Hemophilia Treatment. The growth and trends of Hemophilia Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Hemophilia Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

• Hemophilia A (Severe, Moderate, Mild)
• Hemophilia B (Severe, Moderate, Mild)
• Other Disease Types

By Product

• Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX)
• Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX)
• Extended Half-Life Products (Factor Vill, Factor IX)
• Desmopressin
• Antifibrinolytic Agents
• Gene Therapy Products

By Patient

• Pediatric (0 To 4, 5 To 13, 14 to l8)
• Adult (19 To 44, 45+)

By Treatment

• Prophylaxis
• On Demand

By Therapy

• Factor Replacement Therapy
• Non-Factor Replacement Therapy

By Drug Class

• Vasopressin
• Coagulation Factors

By Route of Administration

• Injectable
• Nasal Spray
• Oral

By End-use

• Hospitals
• Clinics
• Hemophilia Treatment Centers
• Other End-User

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hemophilia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hemophilia Treatment market include Bayer AG, Biogen Inc., Biotest AG (Grifols, S.A.), BioMarin Pharmaceutical Inc, CSL Behring LLC, Ferring BV., Genentech Inc. (Roche Holding AG), Kedrion S.P.A, Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi SA, Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. HEMOPHILIA TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disease Type
  • 3.7.2 Market Attractiveness Analysis By Product
  • 3.7.3 Market Attractiveness Analysis By Patient
  • 3.7.4 Market Attractiveness Analysis By Treatment
  • 3.7.5 Market Attractiveness Analysis By Therapy
  • 3.7.6 Market Attractiveness Analysis By Drug Class
  • 3.7.7 Market Attractiveness Analysis By Route of Administration
  • 3.7.8 Market Attractiveness Analysis By End-use
  • 3.7.9 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY DISEASE TYPE

• 5.1. Overview By Disease Type
• 5.2. Historical and Forecast Data Analysis By Disease Type
• 5.3. Hemophilia A (Severe, Moderate, Mild) Historic and Forecast Sales By Regions
• 5.4. Hemophilia B (Severe, Moderate, Mild) Historic and Forecast Sales By Regions
• 5.5. Other Disease Types Historic and Forecast Sales By Regions

6. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY PRODUCT

• 6.1. Overview By Product
• 6.2. Historical and Forecast Data Analysis By Product
• 6.3. Recombinant Coagulation Factor Concentrates (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
• 6.4. Plasma-Derived Coagulation Factor Concentrates (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
• 6.5. Extended Half-Life Products (Factor Vill, Factor IX) Historic and Forecast Sales By Regions
• 6.6. Desmopressin Historic and Forecast Sales By Regions
• 6.7. Antifibrinolytic Agents Historic and Forecast Sales By Regions
• 6.8. Gene Therapy Products Historic and Forecast Sales By Regions

7. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY PATIENT

• 7.1. Overview By Patient
• 7.2. Historical and Forecast Data Analysis By Patient
• 7.3. Pediatric (0 To 4, 5 To 13, 14 to l8) Historic and Forecast Sales By Regions
• 7.4. Adult (19 To 44, 45+) Historic and Forecast Sales By Regions

8. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY TREATMENT

• 8.1. Overview By Treatment
• 8.2. Historical and Forecast Data Analysis By Treatment
• 8.3. Prophylaxis Historic and Forecast Sales By Regions
• 8.4. On Demand Historic and Forecast Sales By Regions

9. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY THERAPY

• 9.1. Overview By Therapy
• 9.2. Historical and Forecast Data Analysis By Therapy
• 9.3. Factor Replacement Therapy Historic and Forecast Sales By Regions
• 9.4. Non-Factor Replacement Therapy Historic and Forecast Sales By Regions

10. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 10.1. Overview By Drug Class
• 10.2. Historical and Forecast Data Analysis By Drug Class
• 10.3. Vasopressin Historic and Forecast Sales By Regions
• 10.4. Coagulation Factors Historic and Forecast Sales By Regions

11. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 11.1. Overview By Route of Administration
• 11.2. Historical and Forecast Data Analysis By Route of Administration
• 11.3. Injectable Historic and Forecast Sales By Regions
• 11.4. Nasal Spray Historic and Forecast Sales By Regions
• 11.5. Oral Historic and Forecast Sales By Regions

12. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY END-USE

• 12.1. Overview By End-use
• 12.2. Historical and Forecast Data Analysis By End-use
• 12.3. Hospitals Historic and Forecast Sales By Regions
• 12.4. Clinics Historic and Forecast Sales By Regions
• 12.5. Hemophilia Treatment Centers Historic and Forecast Sales By Regions
• 12.6. Other End-User Historic and Forecast Sales By Regions

13. GLOBAL HEMOPHILIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 13.1. Regional Outlook
• 13.2. Introduction
• 13.3. North America Sales Analysis
  • 13.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 13.3.2 North America By Segment Sales Analysis
  • 13.3.3 North America By Country Sales Analysis
  • 13.3.4 United States Sales Analysis
  • 13.3.5 Canada Sales Analysis
  • 13.3.6 Mexico Sales Analysis
• 13.4. Europe Sales Analysis
  • 13.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 13.4.2 Europe By Segment Sales Analysis
  • 13.4.3 Europe By Country Sales Analysis
  • 13.4.4 United Kingdom Sales Analysis
  • 13.4.5 France Sales Analysis
  • 13.4.6 Germany Sales Analysis
  • 13.4.7 Italy Sales Analysis
  • 13.4.8 Russia Sales Analysis
  • 13.4.9 Rest Of Europe Sales Analysis
• 13.5. Asia Pacific Sales Analysis
  • 13.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 13.5.2 Asia Pacific By Segment Sales Analysis
  • 13.5.3 Asia Pacific By Country Sales Analysis
  • 13.5.4 China Sales Analysis
  • 13.5.5 India Sales Analysis
  • 13.5.6 Japan Sales Analysis
  • 13.5.7 South Korea Sales Analysis
  • 13.5.8 Australia Sales Analysis
  • 13.5.9 South East Asia Sales Analysis
  • 13.5.10 Rest Of Asia Pacific Sales Analysis
• 13.6. Latin America Sales Analysis
  • 13.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 13.6.2 Latin America By Segment Sales Analysis
  • 13.6.3 Latin America By Country Sales Analysis
  • 13.6.4 Brazil Sales Analysis
  • 13.6.5 Argentina Sales Analysis
  • 13.6.6 Peru Sales Analysis
  • 13.6.7 Chile Sales Analysis
  • 13.6.8 Rest of Latin America Sales Analysis
• 13.7. Middle East & Africa Sales Analysis
  • 13.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 13.7.2 Middle East & Africa By Segment Sales Analysis
  • 13.7.3 Middle East & Africa By Country Sales Analysis
  • 13.7.4 Saudi Arabia Sales Analysis
  • 13.7.5 UAE Sales Analysis
  • 13.7.6 Israel Sales Analysis
  • 13.7.7 South Africa Sales Analysis
  • 13.7.8 Rest Of Middle East And Africa Sales Analysis

14. COMPETITIVE LANDSCAPE OF THE HEMOPHILIA TREATMENT COMPANIES

• 14.1. Hemophilia Treatment Market Competition
• 14.2. Partnership/Collaboration/Agreement
• 14.3. Merger And Acquisitions
• 14.4. New Product Launch
• 14.5. Other Developments

15. COMPANY PROFILES OF HEMOPHILIA TREATMENT INDUSTRY

• 15.1. Top Companies Market Share Analysis
• 15.2. Market Concentration Rate
• 15.3. Bayer AG
  • 15.3.1 Company Overview
  • 15.3.2 Company Revenue
  • 15.3.3 Products
  • 15.3.4 Recent Developments
• 15.4. Biogen Inc.
  • 15.4.1 Company Overview
  • 15.4.2 Company Revenue
  • 15.4.3 Products
  • 15.4.4 Recent Developments
• 15.5. Biotest AG (Grifols S.A.)
  • 15.5.1 Company Overview
  • 15.5.2 Company Revenue
  • 15.5.3 Products
  • 15.5.4 Recent Developments
• 15.6. Takeda Pharmaceutical Company Limited
  • 15.6.1 Company Overview
  • 15.6.2 Company Revenue
  • 15.6.3 Products
  • 15.6.4 Recent Developments
• 15.7. BioMarin Pharmaceutical Inc
  • 15.7.1 Company Overview
  • 15.7.2 Company Revenue
  • 15.7.3 Products
  • 15.7.4 Recent Developments
• 15.8. CSL Behring LLC
  • 15.8.1 Company Overview
  • 15.8.2 Company Revenue
  • 15.8.3 Products
  • 15.8.4 Recent Developments
• 15.9. Ferring BV.
  • 15.9.1 Company Overview
  • 15.9.2 Company Revenue
  • 15.9.3 Products
  • 15.9.4 Recent Developments
• 15.10. Genentech Inc. (Roche Holding AG)
  • 15.10.1 Company Overview
  • 15.10.2 Company Revenue
  • 15.10.3 Products
  • 15.10.4 Recent Developments
• 15.11. Kedrion S.P.A
  • 15.11.1 Company Overview
  • 15.11.2 Company Revenue
  • 15.11.3 Products
  • 15.11.4 Recent Developments
• 15.12. Novo Nordisk A/S
  • 15.12.1 Company Overview
  • 15.12.2 Company Revenue
  • 15.12.3 Products
  • 15.12.4 Recent Developments
• 15.13. Octapharma AG
  • 15.13.1 Company Overview
  • 15.13.2 Company Revenue
  • 15.13.3 Products
  • 15.13.4 Recent Developments
• 15.14. Pfizer Inc.
  • 15.14.1 Company Overview
  • 15.14.2 Company Revenue
  • 15.14.3 Products
  • 15.14.4 Recent Developments
• 15.15. Sanofi SA
  • 15.15.1 Company Overview
  • 15.15.2 Company Revenue
  • 15.15.3 Products
  • 15.15.4 Recent Developments
• 15.16. Swedish Orphan Biovitrum AB
  • 15.16.1 Company Overview
  • 15.16.2 Company Revenue
  • 15.16.3 Products
  • 15.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies